SavedAdd your journal

Journals / Journal of Health Sciences and Medicine / 2022 / Cilt: 5 - Sayı: 5

The relationship between polycystic ovary syndrome and irritable bowel syndrome

Naziye GÜRKAN
Mehmet AĞAR
Tuğba GÜRBÜZ
Pages
1220–1224
Publication Date
2022-09-25
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: The results showed that IBS prevalence was similar in PCOS (52%) and the control group (50%) (p>0.05).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Polycystic ovary syndrome (PCOS) causes endocrine disorders that affect the functioning of the reproductive system and the body's metabolic system.
📊
Key Findings & Data:Material and Method: In the study, 72 patients were enrolled at gynecology and obstetric clinic in Turkey.
💡
Conclusion & Impact:Results: The results showed that IBS prevalence was similar in PCOS (52%) and the control group (50%) (p>0.05).
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Polycystic ovary syndrome · Irritable bowel syndrome · gastrointestinal symptoms

Abstract

Introduction: Polycystic ovary syndrome (PCOS) causes endocrine disorders that affect the functioning of the reproductive system and the body's metabolic system. Bowel movement disorders and abdominal pain are common complaints of PCOS patients. Few studies have been performed on the relationship between PCOS and irritable bowel syndrome (IBS), and the association between the two syndromes is unclear. Material and Method: In the study, 72 patients were enrolled at gynecology and obstetric clinic in Turkey. The control group were (n=34) and women with PCOS (n=38). IBS diagnosis was made by using Roma IV criteria. Results: The results showed that IBS prevalence was similar in PCOS (52%) and the control group (50%) (p>0.05). No statistically significant association was found between IBS-PCOS and non-IBS-PCOS in terms of gastrointestinal symptoms (p=0.685). These symptoms were associated with PCOS rather than IBS. Significant differences have been observed between IBS-PCOS and non-IBS-PCOS for fasting insulin (FI), luteinizing hormone (LH) and Homeostasis model assessment for insulin resistance (HOMA-IR) (p

🔖

Cite This Article

GÜRKAN, N., AĞAR, M., GÜRBÜZ, T. (2022). The relationship between polycystic ovary syndrome and irritable bowel syndrome. Journal of Health Sciences and Medicine, Cilt: 5 - Sayı: 5, 1220–1224. https://ajindex.com/articles/776439

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Dokuzeylül Güngör N, Güngör K, Yurci A, Cil K, Hatırnaz Ş. Ovarian drilling down-regulates endometrial nuclear factor-κB p65 expression in women with PCOS: A prospective case-control study. Turk J Obstet Gynecol 2022; 19: 45-50.
  2. Hatirnaz E, Hatirnaz S, Kanat-Pektas M, et al. The impact of timing for estrogen supplementation in polycystic ovary syndrome patients undergoing primed in vitro maturation. J Obstet Gynaecol Res 2021; 47: 2684-91.
  3. Dokuzeylul Gungor N, Gurbuz T, Ture T. Prolonged luteal phase support with progesterone may increase papules and plaques of pregnancy frequency in pregnancies through in vitro fertilization. An Bras Dermatol 2021; 96: 171-5.
  4. Dokuzeylül Güngör N, Güngör K. Ovarian stimulation drugs alter the metabolite content of the growing follicle: in vivo spectroscopic evaluation of follicle fluid. J Turk Ger Gynecol Assoc 2021; 22: 132-8.
  5. Wolf WM, Wattick RA, Kinkade ON, Olfert MD. Geographical prevalence of polycystic ovary syndrome as determined by region and race/ethnicity. Int J Environ Res Public Health 2018; 15: 2589. Çetin C, Güngör ND, Yavuz M. First trimester glycosylated hemoglobin for gestational diabetes mellitus screening. Taiwan J Obstet Gynecol 2021; 60: 899-902.
  6. Martin ML, Halling K, Eek D, Krohe M, Paty J. Understanding polycystic ovary syndrome from the patient perspective: a concept elicitation patient interview study. Health Qual Life Outcomes 2017; 15: 162. Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020; 5: 908-17.
  7. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol 2014; 6: 71-80.
  8. Endo Y, Shoji T, Fukudo S. Epidemiology of irritable bowel syndrome. Ann Gastroenterol 2015; 28: 158-9.
  9. Bai T, Xia J, Jiang Y, et al. Comparison of the Rome IV and Rome III criteria for IBS diagnosis: A cross-sectional survey. J Gastroenterol Hepatol 2017; 32: 1018-25.
  10. Kim YS, Kim N. Sex-Gender Differences in Irritable Bowel Syndrome. J Neurogastroenterol Motil 2018; 24: 544-58.
  11. Jiang C, Xu Y, Sharma S, et al. Psychosocial factors associated with irritable bowel syndrome development in chinese college freshmen. J Neurogastroenterol Motil 2019; 25: 233-40.
  12. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712-21.
  13. Zamani M, Alizadeh-Tabari S, Zam